Analyst increased price target and rating for Ligand Pharmaceuticals.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst increased price target and rating for Ligand Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Ligand Pharmaceuticals filed a transaction with the SEC, while Royal Bank of Canada lifted its target price, and the stock is listed on Nasdaq.
- Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.
- Royal Bank of Canada and Truist Financial lowered price targets for Ardent Health, Inc. on July 14, 2026.
- Royal Bank of Canada boosted its price objective for Seabridge Gold, with MarketBeat providing consensus rating data.
- Analyst coverage and company performance data published regarding Jazz Pharmaceuticals, involving MarketBeat, Royal Bank of Canada, and TD Cowen.